WO2011027988A3 - Novel polymorphic form of prasugrel-hydrogen sulfate - Google Patents

Novel polymorphic form of prasugrel-hydrogen sulfate Download PDF

Info

Publication number
WO2011027988A3
WO2011027988A3 PCT/KR2010/005632 KR2010005632W WO2011027988A3 WO 2011027988 A3 WO2011027988 A3 WO 2011027988A3 KR 2010005632 W KR2010005632 W KR 2010005632W WO 2011027988 A3 WO2011027988 A3 WO 2011027988A3
Authority
WO
WIPO (PCT)
Prior art keywords
prasugrel
hydrogen sulfate
polymorphic form
novel polymorphic
novel
Prior art date
Application number
PCT/KR2010/005632
Other languages
French (fr)
Other versions
WO2011027988A2 (en
Inventor
Chang Hee Park
Jong Ouk Baek
Kwee Hyun Suh
Tae Hee Ha
Myoung Sil Ko
Gwan Sun Lee
Eun Young Byun
Original Assignee
Hanmi Holdings Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co., Ltd. filed Critical Hanmi Holdings Co., Ltd.
Publication of WO2011027988A2 publication Critical patent/WO2011027988A2/en
Publication of WO2011027988A3 publication Critical patent/WO2011027988A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Disclosed are: a novel polymorphic form of prasugrel-hydrogen sulfate having improved physical and pharmaceutical properties, a preparation method thereof, and a pharmaceutical composition for preventing or treating an ischemic disease comprising the same.
PCT/KR2010/005632 2009-09-01 2010-08-24 Novel polymorphic form of prasugrel-hydrogen sulfate WO2011027988A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090081911A KR20110024057A (en) 2009-09-01 2009-09-01 Novel polymorphic prasugrel hydrogensulfate
KR10-2009-0081911 2009-09-01

Publications (2)

Publication Number Publication Date
WO2011027988A2 WO2011027988A2 (en) 2011-03-10
WO2011027988A3 true WO2011027988A3 (en) 2011-07-21

Family

ID=43649754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/005632 WO2011027988A2 (en) 2009-09-01 2010-08-24 Novel polymorphic form of prasugrel-hydrogen sulfate

Country Status (2)

Country Link
KR (1) KR20110024057A (en)
WO (1) WO2011027988A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
CN102977116B (en) * 2012-12-24 2014-12-03 天津大学 Amorphous prasugrel hydrogen sulfate and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148023B1 (en) * 1991-09-09 1998-08-17 가와무라 요시부미 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting
WO2007114526A1 (en) * 2006-04-06 2007-10-11 Daiichi Sankyo Company, Limited Process for producing high-purity prasugrel and acid addition salt thereof
CN101177430A (en) * 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 Hydrogenated pyridine derivative and method for preparing salt thereof
CN101255169A (en) * 2008-03-26 2008-09-03 山东大学 Prasugrel salt and preparation method thereof
WO2009066326A2 (en) * 2007-11-19 2009-05-28 Msn Laboratories Limited Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148023B1 (en) * 1991-09-09 1998-08-17 가와무라 요시부미 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting
WO2007114526A1 (en) * 2006-04-06 2007-10-11 Daiichi Sankyo Company, Limited Process for producing high-purity prasugrel and acid addition salt thereof
WO2009066326A2 (en) * 2007-11-19 2009-05-28 Msn Laboratories Limited Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
CN101177430A (en) * 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 Hydrogenated pyridine derivative and method for preparing salt thereof
CN101255169A (en) * 2008-03-26 2008-09-03 山东大学 Prasugrel salt and preparation method thereof

Also Published As

Publication number Publication date
WO2011027988A2 (en) 2011-03-10
KR20110024057A (en) 2011-03-09

Similar Documents

Publication Publication Date Title
HK1210137A1 (en) Process for the preparation of 2,3,3,3-tetrafluoropropene 2333-
EP2022806A4 (en) Process for production of cross copolymers, cross copolymers obtained by the process, and use thereof
WO2009062044A3 (en) Processes for the preparation of prasugrel, and its salts and polymorphs
DK3872058T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
BRPI1008021A2 (en) Method for the manufacture of 2,6-dioxabicyclo- (3.3.0) -octane-4,8-dione
AP2012006135A0 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof.
WO2011042918A3 (en) Improved processes for preparing prasugrel and pharmaceutically acceptable salts thereof
ZA201007526B (en) Process for the preparation of 2,3,3,3-tetrafluoropropene
ZA201007983B (en) Process for the preparation of 2,3,3,3-tetrafluoropropene
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2010062715A3 (en) Polymorphs of dasatinib and process for preparation thereof
EP2106852A4 (en) Catalyst for dehydrogenation of alkyl aromatic compound which has improved physical properties, method for production of the catalyst, and dehydrogenation method
BRPI0819534A2 (en) Pharmaceutical composition, method for treating HIV or AIDS and method for preparing a pharmaceutical composition, dosage form and composition "
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2007132354A3 (en) Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof
EP2394993A4 (en) Novel 2,6-substituted-3-nitropyridine derivative, method for preparing same, and pharmaceutical composition including same
WO2011069032A3 (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof
WO2010098583A2 (en) Novel method for preparing statin compounds or salts thereof, and intermediate compounds used in same
WO2011023954A3 (en) Polymorphic forms of manidipine
ZA200904530B (en) Solid of macrolide compound, method for production thereof, and pharmaceutical composition comprising the same
WO2011027988A3 (en) Novel polymorphic form of prasugrel-hydrogen sulfate
EP2364967A8 (en) Process for preparation of rasagiline and salts thereof
WO2012038971A3 (en) Novel polymorphs of febuxostat
EP2222624A4 (en) Derivatives of 4-nerolidylcatechol, pharmaceutical compositions comprising them and process for producing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10813897

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10813897

Country of ref document: EP

Kind code of ref document: A2